Karen E Hoffman
Overview
Explore the profile of Karen E Hoffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
3504
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez A, Al Hussein Al Awamlh B, Huang L, Zhao Z, Koyama T, Hoffman K, et al.
Urol Oncol
. 2024 Dec;
43(4):271.e19-271.e28.
PMID: 39690079
Objectives: Compare functional outcomes and treatment-related regret over 10 years in Spanish- and English-speaking Hispanic men compared to non-Hispanic men following treatment of localized prostate cancer. Methods And Materials: Data...
2.
Jacomina L, Swanson D, Mitchell M, Woodward W, Smith B, Hoffman K, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
PMID: 39549757
Purpose: Symptomatic locoregionally advanced breast cancer (SLABC) can cause troublesome pain or wound complications that negatively impact quality of life. Although palliative radiation therapy (RT) can minimize tumor-related symptoms, how...
3.
Chung C, Khan M, Olanrewaju A, Pham M, Nguyen Q, Patel T, et al.
Radiother Oncol
. 2024 Nov;
202:110609.
PMID: 39486482
Purpose: Radiation treatment planning is highly complex and can have significant inter- and intra-planner inconsistency, as well as variability in planning time and plan quality. Knowledge-based planning (KBP) is a...
4.
Nguyen D, Barocas D, Zhao Z, Huang L, Koyama T, Al Hussein Ai Awamlh B, et al.
J Cancer Surviv
. 2024 Oct;
PMID: 39400687
Purpose: There is limited evidence of tobacco smoking's effect on cancer survivors' quality of life (QOL) and function. As the natural history of localized prostate cancer (PCa) is protracted, there...
5.
Weng J, Virk R, Kaiser K, Hoffman K, Goodman C, Mitchell M, et al.
JCO Clin Cancer Inform
. 2024 Sep;
8:e2400040.
PMID: 39348612
Purpose: A major barrier to the incorporation of biometric data into clinical practice is the lack of device integration with electronic medical records (EMRs). We developed infrastructure to transmit biometric...
6.
Smith G, Smith B, Wu C, Shaitelman S, Chavez-MacGregor M, Murthy R, et al.
Breast
. 2024 Sep;
78:103813.
PMID: 39321504
Background: We evaluated sociodemographic and clinical predictors of financial toxicity (FT) among patients with breast cancer with higher risk clinical factors warranting regional nodal irradiation (RNI). Methods: Among 183 participants...
7.
Valle L, Jiang T, Rosenbloom A, Zaorsky N, Hwang C, Solanki A, et al.
Eur Urol Oncol
. 2024 Sep;
PMID: 39307608
Background And Objective: Local intraprostatic radiorecurrence of prostate cancer (IPR-PC) can be associated with an aggressive natural history and impact long-term disease-specific survival. While appropriate local salvage intervention can be...
8.
Kouzy R, Ludmir E, Hoffman K, Jhingran A, Kuban D
Pract Radiat Oncol
. 2024 Sep;
14(5):466-467.
PMID: 39218529
No abstract available.
9.
Sosa A, Rooney M, Thames H, Sanders J, Swanson D, Choi S, et al.
Clin Transl Radiat Oncol
. 2024 Aug;
48:100822.
PMID: 39188999
Background: Proton therapy (PT) has unique biologic properties with excellent clinical outcomes for the management of localized prostate cancer. Here, we aim to characterize the toxicity of PT for patients...
10.
Dickstein D, Amarasekera C, Chen R, Nguyen P, Hoffman K
Urol Oncol
. 2024 Jul;
42(11):345-351.
PMID: 38987120
At every stage of the cancer continuum, the management of sexual and gender minorities with prostate cancer requires a thoughtful and multidisciplinary approach. For example, it is important to recognize...